Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines

Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells

(2016) Ann Ager et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer

(2016) Lily Francis et al.   Oncotarget

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization

(2016) K. Newick et al.   Cancer Immunology Research

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

CAR therapy: the CD19 paradigm

(2015) Michel Sadelain   JOURNAL OF CLINICAL INVESTIGATION

Replicating poxviruses for human cancer therapy

(2015) Manbok Kim   JOURNAL OF MICROBIOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

(2015) Tengfei Zhang et al.   Oncotarget

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

(2015) Nobuhiro Nishio et al.   OncoImmunology

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy

(2015) Zuqiang Liu et al.   OncoImmunology

Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity

(2015) Jun Li et al.   NEOPLASIA

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

(2014) N. Nishio et al.   CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells

(2014) Jon G. Quatromoni et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors

(2014) Matteo Santoni et al.   Biomed Research International

Immunotherapeutic Potential of Oncolytic Vaccinia Virus

(2014) Steve H. Thorne   Frontiers in Oncology

Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases

(2013) M. J. Riese et al.   CANCER RESEARCH

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus

(2013) A. Kanerva et al.   CLINICAL CANCER RESEARCH

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

(2012) D. Chinnasamy et al.   CLINICAL CANCER RESEARCH

Crosstalk Between Immune Cell and Oncolytic Vaccinia Therapy Enhances Tumor Trafficking and Antitumor Effects

(2012) Padma Sampath et al.   MOLECULAR THERAPY

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

(2011) M. Hong et al.   CANCER RESEARCH

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

(2011) Jeong Heo et al.   MOLECULAR THERAPY

Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer

(2011) Jun Li et al.   MOLECULAR THERAPY

Treating Tumors With a Vaccinia Virus Expressing IFNβ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity

(2011) Liang-Chuan S Wang et al.   MOLECULAR THERAPY

Regulation of T Cell Activation and Anergy by the Intensity of the Ca2+Signal in Cooperation with Other Signals

(2010) Yu ADACHI et al.   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunotherapy of Murine Hepatocellular Carcinoma by α-Fetoprotein DNA Vaccination Combined with Adenovirus-Mediated Chemokine and Cytokine Expression

(2008) María Matilde Bartolomé Rodríguez et al.   HUMAN GENE THERAPY

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma

(2008) Ta-Chiang Liu et al.   MOLECULAR THERAPY